Luteolysis during two stages of the estrous cycle: subsequent endocrine profiles associated with radiotelemetrically detected estrus in heifers

Our objective was to correlate hormonal changes with the timing and onset of estrus in heifers before and after luteolysis was induced with PGF2 alpha at two stages of the estrous cycle: d 6 to 9 (early; n = 10) or d 14 to 15 (late; n = 10). Blood was collected at intervals of 2 or 12 h to quantify serum concentrations of progesterone, estradiol-17 beta, and LH while heifers were observed visually for estrus and monitored for standing activity by pressure-sensitive, radiotelemetric devices. Although the concentrations of estradiol-17 beta that were associated with the putative appearance of the first dominant follicle declined before luteolysis was induced early in the cycle, some heifers that were given PGF2 alpha were in estrus as early as 35 h. Compared with heifers treated late in the estrous cycle, heifers that were treated early in the cycle produced less progesterone before PGF2 alpha treatment and had greater peak concentrations of estradiol-17 beta at estrus. In addition, heifers that were treated early in the cycle had shorter intervals from PGF2 alpha treatment to estrus, to peak estradiol-17 beta, and to peak LH and to initiation of estrus after the peak in estradiol-17 beta than did heifers treated later in the cycle. The increase in estradiol-17 beta associated with the putative first-wave follicle of the subsequent cycle and the duration of that cycle in early cycle heifers was less than after late cycle luteolysis. Results indicated that greater concentrations of estradiol-17 beta during estrus may be related to the durations of previous cycles and less progesterone exposure before luteolysis. The onset of estrus corresponded closely to, but preceded, the preovulatory LH surge by approximately 3 h.     

Effects of Cis- and trans-clomiphene on the uterine blood flow of oophorectomized ewes

Changes in the left uterine artery blood flow (YBF) after intraarterial administration of estradiol-17beta and cis- and trans-clomiphene citrate to conscious, oophorectomized ewes were monitored by chronically implanted electromagnetic flow probes. Cis-clomiphene produced UBF increases comparable to or greater than those produced by estradiol-17beta but at dose levels 20 times greater. Comparison of UBF response curves for cis-clomiphene with those for estradiol-17beta showed a delayed onset of initial vasodilation and a delayed peak response. The duration of uterine vasodilation produced by cis-clomiphene was dose-dependent and exceeded that produced by estradiol-17beta. Similar reponses were observed with trans-clomiphene but at dose levels at least 1,000 times those of estradiol-17beta. The characteristics of clomiphene-induced UBF responses that differed from those after estradiol-17beta may reflect differences in estrogen receptor activation between the compounds.     

Changes in ovarian function and gonadotropin secretion preceding the onset of nutritionally induced anestrus in Bos indicus heifers

The aim of this study was to monitor endocrine and ovarian changes immediately preceding the onset of nutritionally induced anestrus. Daily blood samples were obtained from 14 postpubertal heifers for one estrous cycle (initial estrous cycle). Subsequently, heifers designated "restricted" were given a limited diet (n = 9), and daily blood samples were obtained for approximately 21 days preceding onset of anestrus (anovulatory cycle). Controls were allowed ad libitum dietary intake (n = 5), and daily blood samples were collected for a complete estrous cycle during a time period that coincided with that preceding onset of anestrus in restricted heifers. Plasma samples were assayed for LH, FSH, progesterone, and estradiol-17 beta. The ovaries of all heifers were examined daily using transrectal ultrasonography from the initial until the final or anovulatory estrous cycles to determine changes in growth of follicles and corpora lutea. Anestrus was defined as failure of ovulation of the dominant follicle following luteolysis. When anovulatory and initial estrous cycles in restricted heifers were compared, mean concentrations of LH were lower (p < 0.01), and diameters of dominant follicles were smaller (p < 0.01); mean concentrations of estradiol-17 beta were also lower in the three days following luteolysis (p = 0.06), but concentrations of FSH appeared to be higher (p = 0.003); maximum diameters of corpora lutea were smaller (p < 0.001), but duration of luteal phases and concentrations of progesterone preceding luteolysis were similar (p > 0.10). In controls, no differences were found between estrous cycles for any of these variables. It is concluded that failure of ovulation, following reduced dietary intake, resulted from insufficient circulating LH to stimulate maturation of the ovulatory follicle.     

Effect of synthetic progestins on the uptake of labelled testosterone and estradiol-17beta by the accessory genital organs of male rats

The effect of pretreatment with norethindrone (NE) or 17-hydroxyprogesterone caproate (17-OHPC) on the uptake of tritiated testosterone and estradiol-17beta by the accessory sex organs of castrated and intact rats was investigated. A selective in vivo increase in the incorporation of tritiated testosterone and estradiol-17beta was observed at 48 hours after castration. The uptake of testosterone was greatest in the epididymis, while the maximum incorporation of estradiol-17beta was by the vas deferens. Pretreatment with NE or 17-OHPC decreased the incorporation of testosterone by all the accessory organs of castrated rats. NE decreased the incorporation of tritiated estradiol-17beta in the epididymis and seminal vesicles only, while 17-OHPC decreased the uptake in all accessory organs.     

The metabolic fate of [3H]estradiol in relation to dietary intake of boron in ovariectomized rats

It has been reported that boron (B) deprivation reversibly lowers plasma estradiol levels in postmenopausal women. In order to establish whether this reflects disturbances in the estrogen catabolic pathway and in particular in catechol estrogen metabolism, the influence of dietary B on the catabolism of [3H]estradiol-17 beta has been studied in ovariectomized rats. Rats were given diets containing < 0.1 or 40 mg B.kg-1, ovariectomized and then infused with [3H]estradiol-17 beta using osmotic pumps. Analysis of urine samples for conjugated, catechol and non-catechol estrogens did not reveal any effects of B on the recovery or the metabolic fate of tritium from the infused estradiol. These results do not therefore support the proposal that B influences estrogen catabolism by interacting with catechol estrogens.     

Inhibin secretion in the mare: localization of inhibin alpha, betaA, and betaB subunits in the ovary

To determine the source of circulating inhibin and estradiol-17beta during the estrous cycle in mares, the cellular localization of the inhibin alpha, betaA, and betaB subunits and aromatase in the ovary was determined by immunohistochemistry. Concentrations of immunoreactive (ir-) inhibin, estradiol-17beta, progesterone, LH, and FSH in peripheral blood were also measured during the estrous cycle in mares. Immunohistochemically, inhibin alpha subunits were localized in the granulosa cells of small and large follicles and in the theca interna cells of large follicles, whereas inhibin betaA and betaB subunits were localized in the granulosa cells and in the theca interna cells of large follicles. On the other hand, aromatase was restricted to only the granulosa cells of large follicles. Plasma ir-inhibin concentrations began to increase 9 days before ovulation; they remained high until 2 days before ovulation, after which they decreased when the LH surge was initiated. Thereafter, a further sharp rise in circulating ir-inhibin concentrations occurred during the process of ovulation, followed by a second abrupt decline. After the decline, plasma concentrations of ir-inhibin remained low during the luteal phase. Plasma estradiol-17beta concentrations followed a profile similar to that of ir-inhibin, except during ovulation, and these two hormones were positively correlated throughout the estrous cycle. Plasma FSH concentrations were inversely related to ir-inhibin and estradiol-17beta. These findings suggest that the dimeric inhibin is mainly secreted by the granulosa cells and the theca cells of large follicles; granulosa cells of small follicles may secrete inhibin alpha subunit, and estradiol-17beta is secreted by the granulosa cells of only large follicles in mares.     

A special closure system of the gastrointestinal tract of the rat (author''s transl)

Serial determinations of FSH, LH, estradiol-17 beta and progesterone in plasma and of total gonadotropins, total estrogens and pregnanediol in urine were performed in 10 adolescent girls between 15 and 19 years of age. Two types of menstrual cycles could be distinguished. The first type is characterized by a nearly normal pattern of FSH, while a preovulatory rise of estradiol-17 beta and an LH-peak is still missing. Only few days prior to menstrual bleeding a small rise of estradiol and progesterone in plasma as well as of estrogens and pregnanediol in urine can be seen, being equivalent to a short luteinization of the follicle without ovulation taking place. The second type already shows all criteria of a regular ovulatory cycle. However the plasma level of LH, estradiol and progesterone and the excretion of estrogens and pregnanediol are still below the average values of control cycles of adult women. On the basis of the hormonal pattern and a shortened luteal phase, a relative insufficiency of this type of cycles is still evident. These studies demonstrate, that the cyclic ovarian function postmenarchial develops gradually and that the onset of ovulation is a marked step in this development. This process of maturition, which is due to the gradual development of the positive feedback of estrogens on the release of LH by the pituitary gland, allows to distinguish in adolescence between cycles before and after maturition of the feed-back mechanism in the ANS.     

Adenosine triphosphate-dependent transport of estradiol-17beta(beta-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells

MDR1, an ABC transporter that confers multidrug resistance in tumor cells, is constitutively expressed in normal liver canalicular membrane. Human MDR1-expressing multidrug-resistant cells display increased resistance to estradiol-17beta(beta-D-glucuronide) (E217G). MDR1 substrates/modulators inhibit adenosine triphosphate (ATP)-dependent transport of E217G in the rat canalicular membrane and protect against E217G-mediated cholestasis in isolated perfused rat liver. The present studies were designed to determine if E217G is a substrate for MDR1 using a baculovirus expression system and if other estrogen glucuronides interact with MDR1. ATP-dependent transport of E217G (10 micromol/L) was linear for up to 2 minutes and yielded a rate of 45.6 pmol/min/mg protein in membrane vesicles from Sf9 cells infected with MDR1-baculovirus. This transport was saturable (Km = 62 micromol/L) and occurred into an osmotically sensitive space. ATP-dependent transport of E217G (10 micromol/L) was inhibited 63% by 10 micromol/L daunomycin, but not by 100 micromol/L S-(2,4-dinitrophenyl)glutathione (GS-DNP) (a substrate for canalicular multispecific organic anion transporter [cMOAT]). Glucuronide conjugates of the estrogen D-ring (100 micromol/L), estriol-17beta(beta-D-glucuronide) (E317G) and estriol-16(beta-D-glucuronide) (E316G), inhibited MDR1-mediated E217G transport by 58% and 35%, respectively. In contrast, noncholestatic glucuronides, estradiol-3-(beta-D-glucuronide) (E23G) or estradiol-3-sulfate-17beta(beta-D-glucuronide) (E23SO417G), had no effect. E217G neither stimulated MDR1 ATPase activity nor inhibited verapamil-stimulated ATPase activity. Infusion of 1.5 micromol/L doxorubicin or 1 micromol/L taxol protected against cholestasis induced by E316G and E317G in isolated perfused rat liver. These studies identify E217G, and probably E316G and E317G, as endogenous substrates for MDR1.     

Cloning, sequencing, expression and characterization of three anti-estradiol-17beta Fab fragments

In order provide data for a basic understanding of the mechanisms of antibody specificity and for the design of antibodies with desired properties, we have sequence-analysed three high affinity anti-estradiol-17beta monoclonal antibodies. All three monoclonal antibodies to estradiol-17beta had been raised by conjugation of the 6-carboxymethyloxime derivative to protein carrier. The genes encoding heavy (Fd) and light (L) chains of these three antibodies were cloned and sequenced. The sequenced antibody chains were found to be from 46.0 to 89.7% sequence identical to a monoclonal antibody (DB3) binding a related steroid, progesterone. The Fd and L chains were paired with all possible Fd-L combinations and the corresponding proteins were expressed in Escherichia coli and characterized for their binding (immunoreactivity) to estradiol-17beta. Under the lac promoter and using the pelB signal sequences the production levels of the soluble (total) heavy and light chain Fab fragment combinations in periplasm and in supernatant varied from 115 to 2207 microg/l, while the immunoreactivity percentages (IR%) varied from < 1 to 45%. The production levels and IR% were dependent on the first constant domain subclasses of the heavy chain as well as the Fd-L chain combination expressed.     

Unconjugated estradiol in the myometrium of pregnancy

By chemically digesting myometrium in a mixture of NaOH and sodium dodecyl sulphate, estradiol could be recovered almost completely by extraction with ethyl acetate. The concentration of estradiol-17beta (E2) in the extracted samples could reliably be determined by radioimmunoassay. Compared to its concentration in the plasma, E2 in the pregnant human myometrium was very low, and as a result, the tissue/plasma estradiol concentration ratio was less than 0.5. In the pseudopregnant rabbit, this ratio ranged between 16 and 20.     

Amino acid composition and endocrine control of vitelline envelope proteins in European sea bass (Dicentrarchus labrax) and gilthead sea bream (Sparus aurata)

The vitelline envelopes of European sea bass and gilthead sea bream are both composed of mainly four proteins with the molecular masses of 90, 52, 48, 45 kDa and 75, 50, 48, 44 kDa, respectively. Each protein has an amino acid composition that is characterized by a high content of proline and glutamic acid and a low content of cysteine, similar to the whole vitelline envelope of both species. The amino acid composition suggests that each protein is distinct but related to the other vitelline envelope proteins. The use of homologous antisera shows that both species have vitelline envelope proteins that are induced by estradiol-17 beta. As males of both species synthesize these proteins after treatment with estradiol-17 beta, the origin is not restricted to the ovaries. Vitellogenin of both European sea bass and gilthead sea bream has the apparent molecular mass of 170 kDa.     

Plasma concentrations of unconjugated estrone, estradiol-17beta and estriol, and HCS throughout pregnancy in diabetics and gestational diabetics

Plasma unconjugated estrone (E1), estradiol-17beta (E2) and estriol (E3), and HCS were measured in the same plasma samples collected throughout pregnancy in 19 gestational diabetics (GD) and 21 diabetics (D). When compared to the results obtained in 22 normal subjects, plasma levels of E1 and E2 were significantly elevated in D in the second half of gestation. The results were intermediate although closer to the normals, in GD. E3 values were not different from the normals in both D and GD. HCS values were lower than normal in early pregnancy in both D and GD. In late pregnancy HCS levels were not different from normal in either D or GD, although some individual values were much above the upper limit in some diabetic patients. The hormonal ratios in D and GD parallel those in normals, although E3/E2 and HCS/E2 were lower in D. These results are discussed with respect to the different behaviour of E2 and E3, taking into account the difference in their respective biosynthetic pathways. Besides a possible quantitative modification of the placental function in D, the results could tentatively be explained by a qualitative change in the fetal estrogen precursors to placental aromatization, in favour of the 16 non-hydroxylated compound. However, maternal modifications in precursor production or in estrogen metabolism can be an alternative hypothesis. Finally, the present work does not support the hypothetical estrogen deficiency in diabetic pregnancy. Estrogen treatment appears to have no objective justification.     

Plasma hormones in clomiphene citrate therapy

Daily plasma follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrone (E1), estradiol-17beta (E2), progesterone (P), androstenedione (A), and testosterone (T) were measured in six clomiphene citrate (Clomid) treated cycles. Three patients ovulated and 1 of them conceived during the study cycle. Three other patients failed to ovulate in spite of some evidence of ovarian response to clomiphene treatment in 2 of them. Plasma gonadotropin levels, of LH in particular, rose during the clomiphene therapy and reached a peak during Day 5 to Day 7 of therapy. Levels of plasma estrogens, both E1 and E2, gradually rose, reflecting follicular maturation in the ovary. When E2 reached a critical level as in the normal ovulatory cycle, it triggered an LH surge which consequently initiated ovulation. When the E2 level was inadequate or excessive, ovulation failed in spite of an LH surge. Following ovulation, plasma P rose and fell in a manner similar to the normal ovulatory cycle, with occasional values that exceeded the normal range. Levels of androgens, both A and T, rose during clomiphene therapy in some cases and T seemed to fluctuate in correlation with LH level. The possible local inhibitory influence of high E2 and T levels on follicular maturation in the ovary during clomiphene therapy is suspected in some cycles in which ovarian response was evident, but ovulation failed to occur.     

Follicle size-dependent induction of prostaglandin G/H synthase-2 during superovulation in cattle

Under physiological conditions, prostaglandin G/H synthase-2 (PGHS-2) is induced in bovine preovulatory follicles by the endogenous surge of gonadotropins. To characterize the pattern of follicular PGHS-2 expression during superovulation in cattle, heifers were treated with exogenous FSH and ovulation was induced with hCG. Animals were ovariectomized 0, 18, and 24 h post-hCG, and extracts of follicles > or = 6 mm were analyzed by Western blotting. Follicular fluid concentrations of prostaglandin (PG) E2, PGF2alpha, progesterone, and estradiol-17beta were determined by RIAs, and the morphology of the cumulus oocyte complex was examined. Results showed that PGHS-2 protein was absent in all follicles isolated at 0 h post-hCG (n = 119) and in small follicles (6 to < 8 mm) isolated between 0 and 24 h post-hCG (n = 27 follicles). In contrast, 12.3% of medium (8 to < 10 mm) and 43.7% of large (> or = 10 mm) follicles were PGHS-2-positive at 18 h post-hCG, and these percentages rose at 24 h to 45.9% and 91.0% in medium and large follicles, respectively (p < 0.05). Follicular fluid concentrations of PGE2 and PGF2alpha were low in follicles isolated at 0 h and increased only in PGHS-2-positive follicles isolated 24 h post-hCG (p < 0.05). Concentrations of progesterone and estradiol-17beta at 0 h were 28.2 +/- 5.8 and 291.8 +/- 13.0 ng/ml, respectively, and a shift from estradiol-17beta to progesterone dominance (luteinization) occurred at 24 h post-hCG only in PGHS-2-positive follicles. Also, expansion of the cumulus oocyte complex was detected at 24 h post-hCG only in PGHS-2-positive follicles. Lack of PGHS-2 induction in follicles of ovulatory size (> 8 mm) was associated with an apparent failure to respond to hCG (absence of luteinization and cumulus expansion). Collectively, these results demonstrate the presence of a time- and follicle size-dependent induction of PGHS-2 in bovine follicles during superovulatory treatment and suggest that PGHS-2 expression can be used as a marker for follicular commitment to ovulation during ovarian hyperstimulation protocols.     

Expression of transforming growth factor-beta 1 messenger ribonucleic acid and the modulation of deoxyribonucleic acid synthesis by transforming growth factor-beta 1 in human endometrial cells

OBJECTIVE: The purpose of this study was (1) to evaluate the potential sites of transforming growth factor-beta 1 synthesis in human endometrium by analyzing separated endometrial glands and stromal cells for transforming growth factor-beta 1 messenger ribonucleic acid by Northern analysis of total ribonucleic acid and (2) to investigate the effects of transforming growth factor-beta 1 on deoxyribonucleic acid synthesis in endometrial epithelial and stromal cells in culture. STUDY DESIGN: Endometrial glands and stroma from proliferative and secretory endometrium were isolated after collagenase treatment of endometrial tissue minces and were analyzed for transforming growth factor-beta 1 messenger ribonucleic acid by Northern analysis. We studied the effects of estradiol-17 beta and transforming growth factor-beta 1 on deoxyribonucleic acid synthesis in endometrial epithelium and transforming growth factor-beta 1 on stromal cells in culture by evaluating tritiated thymidine incorporation into trichloroacetic acid-precipitable material. RESULTS: Transforming growth factor-beta 1 messenger ribonucleic acid was detected for Northern analysis in separated endometrial stromal cells in levels that were greatest during the secretory phase and in greater levels than in epithelial cells from that same tissue. Transforming growth factor-beta 1 messenger ribonucleic acid in glandular epithelium in culture was not increased to detectable levels by treatment with transforming growth factor-beta 1. Deoxyribonucleic acid synthesis in endometrial glandular epithelium was inhibited by transforming growth factor-beta 1, but transforming growth factor-beta 1 stimulated deoxyribonucleic acid synthesis in endometrial stromal cells in culture. After treatment for 5 days with estradiol-17 beta (10(-8) mol/L), deoxyribonucleic acid synthesis in endometrial glands in culture was decreased by 40%. Transforming growth factor-beta 1 (1 ng/ml) did not alter this effect of estradiol-17 beta on deoxyribonucleic acid synthesis. CONCLUSIONS: Transforming growth factor-beta 1 acts to decrease deoxyribonucleic acid synthesis in epithelial cells and to increase it in stromal cells isolated from human endometrium and maintained in monolayer culture. Transforming growth factor-beta 1, potentially of stromal cell origin, could participate in the regulation of endometrial cell proliferation and differentiation in vivo.     

Enzymatic sulfation of steroids: II. The control of the hepatic cortisol sulfotransferase activity and of the individual hepatic steroid sulfotransferases of rats by gonads and gonadal hormones

Ovariectomy has relatively little effect on hepatic cortisol sulfotransferase activity (HCSA) in female rats, diminishing it only 30%. On the other hand, castration more than doubles HCSA in males. HCSA is due to 3 steroid sulfotransferases, STI, STII, and STIII. Its dimunition in ovariectomized rats is due to decreased STI and STII. Castration of males results in elevation of STII. Thus, ovaries appear to stimulate STI and STII production and testes appear to inhibit production of STII and perhaps STI. Studies with testosterone and estradiol-17beta support a role for sex hormones as mediators of gonadal effects on HCSA, by stimulating or inhibiting production of the individual enzymes. Estradiol-17beta administration reverses the effect of ovariectomy on HCSA. Testosterone administration to intact or castrated females decreases HCSA by 60-70%, due to disappearance of all STI and most STII activity. Thus, androgen administration appears to suppress both STI and STII production. In intact males testosterone administration elevates HCSA 70-80% due to increased STIII. Estradiol-17beta administration to intact or castrated males elevates HCSA 9-10-fold. In intact animals this is due to elevated STI and STII but not STIII. In castrates all three enzymes are elevated by the estrogen.     

Influence of prostatic secretion protein on uptake of androgen-receptor complex in prostatic cell nuclei

Prostatic secretion protein (PSP) is a major component of rat prostatic cytosol, and this protein is also found in the prostatic fluid. Purified PSP was found to inhibit the nuclear uptake of the [3H]methyltrienolone-receptor complex in vitro. Furthermore, purified PSP inhibited the binding of this androgen-receptor complex to DNA-cellulose. It is suggested that these effects of PSP may represent an intracellular control system regulating the concentration of PSP. Administration of estramustine, the dephosphorylated metabolite of the anti-cancer drug estramustine phosphate (Estracyt), to rats was found to decrease the weight of the prostate gland but to maintain the concentration of PSP, calculated as mg PSP/mg protein, at a constant level. In contrast, castration or administration of estradiol-17 beta valerate decreased the weight of the prostate gland as well as the concentration of PSP. These findings indicate that the mechanism of action of estramustine is at least partially different from that of estradiol-17 beta. Furthermore, it is suggested that estramustine may exert part of its action through its effects on the concentration of PSP.     

Effect of estradiol-17 beta on preprolactin messenger ribonucleic acid activity in the rat pituitary gland

Rat pituitary RNA was translated in the wheat germ system. Preprolactin messenger RNA activity was estimated by adsorption of cell-free products to solid phase antiprolactin. When male rats were injected for 4 days with estradiol-17beta, pituitary preprolactin mRNA activity was increased 2.5- to 3.0-fold over controls. This increase was evident when either total RNA, poly(adenylic acid) RNA, or polysomal RNA was translated in the cell-free system. In male rats receiving daily injections of estradiol-17beta, preprolactin mRNA activity was increased to an apparent maximum of 300% of controls after 7 days of treatment. Our data also indicate that estradiol increases preprolactin mRNA activity per microgram of RNA as well as the pituitary content of RNA. After estradiol treatment was discontinued, preprolactin mRNA activity declined to 50% of the maximum stimulation after approximately 2 days. In ovariectomized retired breeder female rats, a 5-fold increase in preprolactin activity over ovariectomized controls was obtained. In other studies, a 2-fold increase in preprolactin mRNA activity was obtained in male rats 24 h after a single injection of pimozide, a dopamine blocking drug.